IL1RL1 and leukemia: To further assess the impact of anti-murine Il1rl1 T-BsAb in an alternative clinically relevant immunocompetent leukemia model, we utilized the epigenetic DNMT3A/FLT3ITD leukemic model, which frequently develops extramedullary leukemia in the spleen and liver58.